Clinical utility of digital technologies in Parkinson’s disease

Digital health technologies (DHTs) are on the verge of changing treatment of Parkinson's disease (PD). This narrative overview article describes DHTs that are already used or in development, focusing on technologies available in Germany and on their clinical utility. Examples include applications that are primarily used by patients, i.e., tools for patient education and empowerment, but also stand-alone interventions improving clinical outcomes including motor and non-motor symptoms. In Germany, these patient-centered DHTs fall under the HTA framework of digital health applications (DIGA). DHT for telemonitoring, in contrast, are designed to support physicians and other healthcare providers and therefore medical devices. DHT are also used increasingly as exploratory endpoints in trials testing neuroprotective treatments.

Authors

Institutions

Publication Details

Journal
Journal of Neural Transmission
Published
2025-11-12
DOI
https://doi.org/10.1007/s00702-025-03062-3
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical utility of digital technologies in Parkinson’s disease

Christoph Redecker, Jürgen Winkler, Björn Falkenburger, Jochen Klucken et al.
Journal of Neural Transmission
Parkinson's Disease Mechanisms and Treatments
article

Clinical utility of digital technologies in Parkinson’s disease

Christoph Redecker, Jürgen Winkler, Björn Falkenburger, Jochen Klucken, Günter U. Höglinger, Thilo van Eimeren, Monika Pötter‐Nerger, Alessandra Fanciulli, Joseph Claßen
article en

Abstract

Digital health technologies (DHTs) are on the verge of changing treatment of Parkinson's disease (PD). This narrative overview article describes DHTs that are already used or in development, focusing on technologies available in Germany and on their clinical utility. Examples include applications that are primarily used by patients, i.e., tools for patient education and empowerment, but also stand-alone interventions improving clinical outcomes including motor and non-motor symptoms. In Germany, these patient-centered DHTs fall under the HTA framework of digital health applications (DIGA). DHT for telemonitoring, in contrast, are designed to support physicians and other healthcare providers and therefore medical devices. DHT are also used increasingly as exploratory endpoints in trials testing neuroprotective treatments.

Journal of Neural TransmissionVol. 133(2)
Innsbruck Medical University (AT), Universität Hamburg (DE), Centre Hospitalier de Luxembourg (LU), Friedrich-Alexander-Universität Erlangen-Nürnberg (DE), University of Luxembourg (LU), Universität Innsbruck (AT), German Center for Neurodegenerative Diseases (DE), LMU Klinikum (DE), Munich Cluster for Systems Neurology (DE), Klinikum Lippe (DE), University Hospital Cologne (DE), Technische Universität Dresden (DE), Ludwig-Maximilians-Universität München (DE), Leipzig University (DE)
Openalex Percentile: Top 53%
Parkinson's Disease Mechanisms and Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.